Metraipolis › archive › dc_764eba5e3035

Cost-effectiveness of degarelix versus LHRH agonists in prostate cancer: a systematic review — Europe PMC PMID:41948305

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41948305
DOI
10.3389/frhs.2026.1608532
License (as archived)
solo-consultazione
Archived
2026-11-04T01:50:46.874Z
SHA-256 of the archived text
2d1caa644775caae1d1351c8a5c04f7dc11492aecdee124b5bc9ba7d5f355ae2
Stable URL of this page
https://metraipolis.com/documento/dc_764eba5e3035

How to cite

Cost-effectiveness of degarelix versus LHRH agonists in prostate cancer: a systematic review — Europe PMC PMID:41948305 — Europe PMC (en), https://europepmc.org/article/MED/41948305 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_764eba5e3035 (Metraipolis archive dc_764eba5e3035, sha256 2d1caa644775caae1d1351c8a5c04f7dc11492aecdee124b5bc9ba7d5f355ae2)
BibTeX
@misc{dc764eba5e3035,
  title = {Cost-effectiveness of degarelix versus LHRH agonists in prostate cancer: a systematic review — Europe PMC PMID:41948305},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41948305},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_764eba5e3035; sha256 2d1caa644775caae1d1351c8a5c04f7dc11492aecdee124b5bc9ba7d5f355ae2},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41948305. Agents can read the archived copy with the MCP tool read_document.